trending Market Intelligence /marketintelligence/en/news-insights/trending/Of6l6rgS_yfLx28qQi4Jfg2 content esgSubNav
In This List

COSMOS Pharmaceutical fiscal Q1 profit falls YOY

Blog

Using ESG Analysis to Support a Sustainable Future

Video

S&P Capital IQ Pro | Powered by Expert Insights

Blog

Q&A: Streamlining Analytics for TCFD Reporting

Blog

Evergrande and the wider impact: a sentiment analytics based perspective


COSMOS Pharmaceutical fiscal Q1 profit falls YOY

COSMOS Pharmaceutical Corp. said its normalized net income for the fiscal first quarter ended Aug. 31 was ¥148.87 per share, a decrease of 14.7% from ¥174.43 per share in the prior-year period.

Normalized net income, which excludes unusual gains or losses on a pre- and after-tax basis, was ¥2.95 billion, a decline of 14.7% from ¥3.45 billion in the prior-year period.

The normalized profit margin declined to 2.8% from 3.7% in the year-earlier period.

Total revenue grew 11.7% year over year to ¥104.75 billion from ¥93.76 billion, and total operating expenses increased 13.4% on an annual basis to ¥100.39 billion from ¥88.51 billion.

Reported net income fell 13.0% from the prior-year period to ¥2.71 billion, or ¥137.07 per share, from ¥3.12 billion, or ¥157.63 per share.

As of Oct. 14, US$1 was equivalent to ¥107.05.